The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Overall survival with everolimus, sunitinib, and placebo for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison of randomized trials.
James E. Signorovitch
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Elyse Swallow
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Evan Kantor
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Xufang Wang
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Tomas Hass
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Judith Klimovsky
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Peter Metrakos
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Expert Testimony - Novartis